Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.
KIRhub 2.0
Sign in

MNG453

e9d1ed66-46a7-5d5f-9ad6-45be270084c4

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
cancer_type_detailed
subtype

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

  • PANCREAS_BETA_CELLS+0.351
  • PROTEIN_SECRETION+0.280
  • OXIDATIVE_PHOSPHORYLATION+0.220
  • SPERMATOGENESIS+0.158
  • XENOBIOTIC_METABOLISM+0.147
  • FATTY_ACID_METABOLISM+0.052
  • MYC_TARGETS_V1+0.039
  • MTORC1_SIGNALING+0.034
  • BILE_ACID_METABOLISM-0.006
  • ANGIOGENESIS-0.022

Top 10 suppressed

  • TNFA_SIGNALING_VIA_NFKB-0.542
  • INTERFERON_GAMMA_RESPONSE-0.462
  • INTERFERON_ALPHA_RESPONSE-0.453
  • ALLOGRAFT_REJECTION-0.450
  • IL6_JAK_STAT3_SIGNALING-0.445
  • INFLAMMATORY_RESPONSE-0.421
  • E2F_TARGETS-0.409
  • MYC_TARGETS_V2-0.406
  • MITOTIC_SPINDLE-0.400
  • EPITHELIAL_MESENCHYMAL_TRANSITION-0.387

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

7 twins match this tumor's tissue · 3 come from a different tissue of origin

#SampleCancer typeSubtypecos similarity
1MDT-AP-2960
medullo-epn-umap@date-based
MedMedulloblastoma0.892
2SRR35579848
breast-umap@18
B0.883
3TCGA-37-4129-01A-01R-1100-07
lung-landscapes@6
cohortSC0.880
4TCGA-D8-A1XV-01A-11R-A14M-07
breast-umap@18
B0.865
5SRR25617889
breast-umap@18
B0.858
6SAMN03290937
melanoma-umap@29
0.856
7TCGA-E9-A245-01A-22R-A16F-07
breast-umap@18
B0.855
8SRR10899984
melanoma-umap@29
0.848
9SRR1464327
brain-umap@2
GTEX0.844
10SRR1072504
brain-umap@2
GTEX0.844

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 8 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
PANCREAS_BETA_CELLS0.351Cobimetinib— uncovered
PROTEIN_SECRETION0.280Remibrutinib— uncovered
OXIDATIVE_PHOSPHORYLATION0.220Remibrutinib— uncovered
SPERMATOGENESIS0.158Inavolisib— uncovered
XENOBIOTIC_METABOLISM0.147Inavolisib— uncovered
FATTY_ACID_METABOLISM0.052Inavolisib— uncovered
MYC_TARGETS_V10.039Inavolisib— uncovered
MTORC1_SIGNALING0.034Inavolisib— uncovered